Company intelligence / Profile preview

CancerVax

Ownership: Private
Development stage: Other

Overview

CancerVax is a pre-clinical biotechnology company developing a universal immunotherapy platform designed to train the immune system to detect, mark, and kill only diseased cells. Their lead program targets Ewing sarcoma; additional programs are in early-stage research with no clinical trial results yet reported. The company collaborates closely with UCLA on foundational research.[3][8][10]

Therapeutic areas: Oncology
Modalities: Immunotherapy (cancer vaccines)CAR-T cell therapy (universal and personalized)mRNA-based therapeutics (Smart mRNA technology)Nanoparticle delivery systems[1][5][7][9]
Industry: Biotech

Drug pipeline

4 assets

polyvalent allogeneic cell vaccine

Preclinical

3 more assets in the full pipeline.

Partnerships

University of California Los Angeles (UCLA): major academic R&D partner with exclusive licensing agreements for resulting IP.[10]

Beyond the preview

Go deeper on CancerVax.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CancerVax.